最近工业富联在资本市场的热度简直挡不住——股价一路高歌猛进，直逼万亿市值关口，更带着整个电 子行业"逆袭"，市值一举超过银行业，成了A股史上头一遭的新鲜事。很多人可能还在纳闷儿，不就是 一家代工厂吗，怎么就一飞冲天了。如果还是这样的看法，只能说你真的不懂工业富联，这股涨势背后 藏着一个新的认知：工业富联正以其深度的数字化布局与技术输出，悄然改变全球制造业的底层逻辑。 重构制造的底层运行逻辑 很多人对工业富联的印象，还停留在"靠大客户的制造企业"，但真扒开它的业务盘就会发现，它早不只 是"造东西"那么简单。它搭了套覆盖生产全流程的数字制造体系：设备怎么联动、数据怎么流转，都织 成了一张密不透风的工业协同网。有了这张网，制造环节总算有了"实时感知、动态调整"的本事——以 前工厂出问题得等人发现、凭经验排查，现在机器自己能盯着生产，苗头不对立刻调整。 更关键的是它的野心。别家还在死磕"降本增效"时，它已在搭工业标准化协作框架；外界以为它只守着 生产线时，它早开始打磨未来制造的技术体系。说白了，它不想只当产业链"参与者"，更想做制造业升 级的"基建工"——像盖楼时不先砌墙，而是稳稳打下撑住整栋楼的地基。 AI落地生产 ...

Group 1: Overseas Market Strategy - The company views overseas markets as having significant growth potential, with a focus on leveraging technological strength and brand influence for expansion [1] - In Europe, the acquisition of Clínica Baviera S.A. (CB) has led to a revenue of €260 million in 2024, with a network of 137 clinics, nearly doubling since acquisition [1][2] - CB's revenue growth has shown a compound annual growth rate (CAGR) of over 15% since acquisition, with net profit growing at over 20% [2] Group 2: Southeast Asia Expansion - The acquisition of ISEC in Southeast Asia has resulted in a revenue of SGD 74 million in 2024, with 17 clinics established [2] - ISEC has experienced a CAGR of approximately 20% in revenue and nearly 30% in net profit since acquisition [2] - The company is actively seeking opportunities in Southeast Asian markets, which have a population of nearly 700 million, indicating substantial growth potential [2] Group 3: Domestic Growth Potential - The company operates 252 hospitals domestically, with 194 being acquired through funds, indicating a significant existing network [4] - There is considerable growth potential in provincial hospitals, with some generating over CNY 200 million in revenue but still having low penetration rates [4] - County-level hospitals are expected to grow as economic development and public awareness of eye health increase [4][5] Group 4: Cost Reduction and Efficiency - The company emphasizes cost reduction and efficiency improvements regardless of growth rates, aiming for healthier growth [6] - In 2025, the company initiated organizational changes to enhance operational efficiency and attract talent for high-quality development [6] - The focus on patient-centered care and digital transformation aims to convert data and network advantages into new productivity [6] Group 5: Market Opportunities in Presbyopia Treatment - The presbyopia treatment market in China is still in its early stages, with significant growth potential due to low awareness among the elderly [7] - The company plans to develop presbyopia diagnosis and treatment services, including establishing specialized clinics [7] - The European subsidiary has successfully developed presbyopia surgery, indicating a model for future growth in China [7] Group 6: New Technology Promotion - The company maintains a leading position in refractive technology, with new procedures like all-laser LASIK and ICL V5 being introduced [8] - New technologies have improved patient outcomes and helped reverse the trend of declining average prices [8] - The company leverages its network and brand advantages to accelerate the promotion of new technologies in the domestic market [8]

Core Viewpoint - Yanjing Beer has achieved significant revenue and net profit growth due to product structure optimization, cost control, and market expansion [1][2][3] Financial Performance - The company expects a net profit of 1.062 billion to 1.137 billion yuan for the first half of 2025, representing a year-on-year growth of 40% to 50% [1][3] - From 2020 to 2024, Yanjing Beer's revenue increased from 10.928 billion yuan to 14.667 billion yuan, a cumulative growth of 34%, while net profit surged from 197 million yuan to 1.056 billion yuan, an increase of over 400% [2][3] Brand Value - Yanjing Beer was included in the "China's 500 Most Valuable Brands" list with a brand value of 237.9 billion yuan in 2025, up from 180.575 billion yuan in 2023 and 223.695 billion yuan in 2024 [3] Product Strategy - The company has focused on a big product strategy and expansion of mid-to-high-end production capacity, with the revenue share of mid-to-high-end products rising from 59.81% in 2020 to 67.01% in 2024 [1][4] - The Yanjing U8 product has seen an average annual sales growth of over 30% since its launch in 2020, with sales exceeding 5 billion yuan in 2024, accounting for 35% of the company's beer business revenue [4] Market Expansion - Yanjing Beer has entered international markets through Southeast Asian agents, achieving export revenue of 120 million yuan in 2024, a 40% year-on-year increase [4] - The company has diversified its product line by launching beverages like Beistejia soda and health foods, with non-beer business revenue reaching 820 million yuan in 2024, a 22% increase [5]

Investment Rating - The report assigns a rating of "Buy" for the company, with a target price based on the latest closing price of 32.91 [5]. Core Insights - The company achieved a total operating revenue of 11.788 billion yuan in 2024, representing a year-on-year growth of 20.55%. The net profit attributable to shareholders was 2.05 billion yuan, an increase of 2.42% year-on-year. In Q1 2025, the company reported total operating revenue of 3.303 billion yuan, a year-on-year increase of 25.13%, and a net profit of 0.58 billion yuan, up 42.15% year-on-year, with a non-recurring net profit growth of 103% [1][3]. Summary by Sections 1. Stable Demand for Flexible Employment - The flexible employment segment showed resilience, driving steady revenue growth. In 2024, the company’s operating revenue reached 11.8 billion yuan, with flexible employment revenue growing by 22% [2][14]. - In Q1 2025, the company’s flexible employment service dispatched 146,000 personnel, a year-on-year increase of 26% [2][14]. 2. Profit Improvement through Cost Reduction and Government Subsidies - The company’s net profit for 2024 was 205 million yuan, with a non-recurring net profit of 139 million yuan, reflecting a year-on-year increase of 2.4% and 3.57%, respectively. In Q1 2025, net profit and non-recurring net profit grew by 42% and 103% year-on-year, respectively, primarily due to increased government subsidies and effective cost control [3][33]. 3. AI Development and Growth of HeWa Platform - The company invested 169 million yuan in technology in 2024, maintaining annual investments above 100 million yuan since 2021. The HeWa platform saw significant growth, with registered partners increasing by 21.76% year-on-year to over 16,200 [4][41]. 4. Earnings Forecast - The company is expected to achieve operating revenues of 14.779 billion yuan, 18.024 billion yuan, and 21.266 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 25%, 22%, and 18%. The net profit attributable to shareholders is projected to be 278 million yuan, 337 million yuan, and 395 million yuan for the same years, with corresponding growth rates of 35%, 21%, and 17% [8][46].